# US 2010/0168029 A1 · Methods for treating bone tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168029 A1
- Document ID: US20100168029A1
- Status: Published application
- Kind: A1
- Application number: 12/721,244
- Filed: 2010-03-10
- Published: 2010-07-01
- Earliest claimed: 2004-09-09
- Inventors: John C. Lee; Carol A. Toth
- Web page: https://patentgrep.com/patent/US20100168029A1

## CPC

- A61K 38/1875: {Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor}
- A61P 35/00: Antineoplastic agents
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods of treating bone cancer, inducing differentiation of bone tumor cells, inhibiting bone tumor growth, inducing bone tumor regression or treating a hyperproliferative cell disorder by administering a pharmaceutically effective amount of a bone morphogenic protein or a nucleic acid encoding the bone morphogenic protein.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A method of treating a secondary bone cancer in a mammal comprising the step of administering to the mammal a pharmaceutically effective amount of OP-1 or a nucleic acid encoding OP-1.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the secondary bone cancer metastasized from breast, lung or prostate.

### Claim 19

A method of inducing regression of a secondary bone cancer in a mammal comprising the step of administering to the mammal a pharmaceutically effective amount of OP-1 or a nucleic acid encoding OP-1.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the secondary bone cancer metastasized from breast, lung or prostate.

### Claim 21 (depends on 17, 18, 19, 20)

The method according to any one of claims 17 to 20, wherein the nucleic acid is a viral vector comprising a gene that encodes OP-1, and wherein the viral vector is selected from the group consisting of an adenoviral vector, a lentiviral vector, a baculoviral vector, an Epstein Barr viral vector, a papovaviral vector, a vaccinia viral vector and a herpes simplex viral vector.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the viral vector is selected from the group consisting of an adenoviral vector, a baculoviral vector and a lentiviral vector.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the viral vector is an adenoviral vector.

### Claim 24 (depends on 17, 18, 19, 20)

The method according to any one of claims 17 to 20, wherein OP-1 or the nucleic acid encoding OP-1 is formulated as a gel, an aqueous solution, a paste or a putty.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the formulation is a sustained release formulation.

### Claim 26 (depends on 24)

The method according to claim 24, wherein OP-1 or the nucleic acid encoding OP-1 is formulated for local administration.